COMPOSITION:
DAPASIS M:
Each tablet contains Dapagliflozin Propanediol Monohydrate equivalent to Dapagliflozin 5 mg and Metformin extended-release 500 mg.
Mechanism of Action:
Dapagliflozin:
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increasing urinary glucose excretion.
Metformin is an antihyperglycemic agent that improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike sulfonylureas, metformin does not produce significant hypoglycemia in either patients with type 2 diabetes or normal subjects and does not cause hyperinsulinemia.